

Old and New TB Drugs: Mechanisms of Action and Resistance

Anastasia S. Kolyva and Petros C. Karakousis
Johns Hopkins University Center for Tuberculosis Research
Baltimore, M.D.,
USA

1. Introduction

Historically, tuberculosis (TB) has been associated with significant morbidity and mortality, and still remains a major global health problem. It is estimated that 2 billion people are latently infected with *Mycobacterium tuberculosis*, resulting in approximately 3 million deaths worldwide per year. Among the unique features of this organism is its ability to establish persistent infection, requiring prolonged antibiotic treatment in order to achieve clinical cure. The basic goals of anti-tuberculosis therapy include rapid killing of actively multiplying bacilli, prevention of acquired drug resistance, and sterilization of infected host tissues to prevent clinical relapse. Official guidelines recommend a minimum of 6 months of combination antibiotic therapy in order to achieve these goals. Clinical isolates in geographic areas with a high prevalence of drug resistance should be tested routinely for susceptibility to first-line anti-tuberculosis agents if resources permit, in order to optimally guide therapy (Karakousis 2009). The emergence of multidrug-resistant TB (MDR-TB), defined as resistance to the first-line drugs isoniazid and rifampicin, and extensively drug-resistant TB (XDR-TB), defined as MDR-TB with additional resistance to fluoroquinolones and at least one of the injectable second-line drugs (capreomycin, kanamycin, and amikacin), poses formidable challenges to global TB control efforts. The high global incidence of drug-resistant TB, estimated annually to be ~500,000 cases of MDR-TB of which 5% to 7% represent XDR-TB, underscores the need to understand the molecular mechanisms of drug resistance, with the ultimate goals of developing new techniques for rapid detection of drug resistance and identification of new drug targets.

This chapter presents an updated review of the mechanisms of action and resistance of the main old and new anti-tuberculosis agents.

2. Intrinsic and acquired drug resistance

Intrinsic resistance refers to the innate ability of a bacterium to resist the activity of a particular antimicrobial agent through its inherent structural or functional characteristics. Intrinsic drug resistance in *M. tuberculosis* has been attributed to its unique cell wall properties, including the presence of mycolic acids, which are high-molecular-weight α -alkyl, β -hydroxy fatty acids covalently attached to arabinogalactan, and which constitute a


very hydrophobic barrier responsible for resistance to certain antibiotics (Karakousis, Bishai et al. 2004). In addition, *M. tuberculosis* possesses β -lactamase enzymes, which confer intrinsic resistance to β -lactam antibiotics, while efflux mechanisms appear to play an important role in resistance to antibiotics such as tetracycline and the aminoglycosides.

Acquired drug resistance occurs when a microorganism obtains the ability to resist the activity of a particular antimicrobial agent to which it was previously susceptible. Acquired drug resistance in *M. tuberculosis* is caused mainly by spontaneous mutations in chromosomal genes, and the selective growth of such drug-resistant mutants may be promoted during suboptimal drug therapy (Kochi, Varelzdis et al. 1993). The rate of genetic mutations leading to resistance varies somewhat among anti-tuberculosis drugs, from a frequency of $\sim 10^{-5}$ - 10^{-6} organisms for isoniazid to $\sim 10^{-7}$ - 10^{-8} organisms for rifampin (Karakousis 2009). Since the bacterial burden typically present in pulmonary cavities does not exceed 10^{12} bacilli (Canetti 1965), combination therapy is highly effective for drug-susceptible disease, and the risk for development of acquired drug resistance is minimized.

3. Old TB drugs

3.1 Isoniazid

Isoniazid (isonicotinic acid hydrazide, INH) has been the most commonly used anti-tuberculosis since recognition of its clinical activity in 1952 (Robitzek and Selikoff 1952). Consisting of a pyridine ring and a hydrazide group, INH is a nicotinamide analog, structurally related to the anti-tuberculosis drugs ethionamide and pyrazinamide. Because of its significant bactericidal activity, it has become a critical component of the first-line antituberculous regimens, although in the last two decades resistance to INH has been reported with increasing frequency.



Isoniazid

3.1.1 Mechanism of action

INH appears to penetrate host cells readily (Mackaness and Smith 1952) and diffuses across the *M. tuberculosis* membrane (Suter 1952; Bardou, Raynaud et al. 1998). INH is a pro-drug, requiring oxidative activation by the *M. tuberculosis* catalase-peroxidase enzyme KatG (Zhang, Heym et al. 1992). Although the active metabolites of INH have been reported to inhibit multiple essential cellular pathways, including synthesis of nucleic acids (Gangadharam, Harold et al. 1963), phospholipids (Brennan, Rooney et al. 1970), and NAD metabolism (Zatman, Kaplan et al. 1954; Bekierkunst 1966), the primary pathway

responsible for the killing activity of the drug is mycolic acid synthesis (Winder and Collins 1970; Takayama, Wang et al. 1972; Takayama, Schnoes et al. 1975). Thus, the activated form of the drug binds tightly to the NADH-dependent enoyl acyl carrier protein (ACP) reductase *InhA* (Banerjee, Dubnau et al. 1994), a component of the fatty acid synthase II system of mycobacteria, which is essential for fatty acid elongation (Quemard, Sacchetti et al. 1995). INH does not directly interact with *InhA*, as X-ray crystallographic and mass spectrometry data revealed that the activated form of INH covalently attaches to the nicotinamide ring of NAD bound within the active site of *InhA*, causing NADH to dissociate from *InhA* (Dessen, Quemard et al. 1995; Rozwarski, Grant et al. 1998). However, the precise mechanism by which INH kills *M. tuberculosis* remains to be elucidated.

3.1.2 Mechanism of resistance

Because INH is the most commonly used antituberculosis drug, resistance to INH occurs more frequently among clinical isolates than resistance to any other agent (Karakousis 2009).

Mutations in INH-resistant clinical isolates are most commonly detected in the *katG* gene, occurring in 50–80% of cases, thus reducing the ability of the catalase-peroxidase to activate the INH pro-drug. The *katG* gene is located in a highly variable and unstable region of the *M. tuberculosis* genome, with missense and nonsense mutations, insertions, deletions, truncation and, more rarely, full gene deletions observed. Depending on the type of mutation, and the degree to which function of the KatG enzyme is preserved, the ensuing minimum inhibitory concentration (MIC) of isoniazid may range from 0.2 to 256 mg/L. Point mutations in *katG* are more commonly observed than other types of mutations, and a single point mutation resulting in substitution of threonine for serine at residue 315 (S315T) accounts for the majority of INH resistance among clinical isolates (Marttila, Soini et al. 1998; Abate, Hoffner et al. 2001). The S315T mutation results in a significant reduction in catalase and peroxidase activity, and is associated with high-level INH resistance (MIC = 5–10 µg/mL) (Rouse, DeVito et al. 1996; Saint-Joanis, Souchon et al. 1999).


INH resistance may also arise from mutations in *inhA*, resulting in reduced affinity of the enzyme for NADH without affecting its enoyl reductase activity (Basso, Zheng et al. 1998), or in the promoter region of the *mabA*/*inhA* operon (Musser, Kapur et al. 1996), resulting in overexpression of the wild-type enzyme. Generally, mutations in *inhA* or in the promoter region of its operon usually confer low-level resistance (MIC = 0.2–1 mg/L) (Wade and Zhang 2004). In addition to conferring resistance to INH, mutations in *inhA* also cause resistance to the structurally related second-line drug ethionamide.

Mutations in the *ndh* gene, which encodes a NADH dehydrogenase, confer resistance to INH and ethionamide in *M. smegmatis* (Miesel, Weisbrod et al. 1998), and have been detected in INH-resistant *M. tuberculosis* clinical isolates, which lack mutations in the *katG* or *inhA* genes (Lee, Teo et al. 2001). Defective NADH dehydrogenase could lead to an increased ratio of NADH/NAD, thereby interfering with KatG-mediated peroxidation of INH, or by displacing the INH/NAD adduct from the *InhA* active site (Miesel, Weisbrod et al. 1998). Furthermore, mutations in *kasA* and *ahpC* genes have been associated with INH resistance. Nevertheless, as many as a quarter of all clinical INH-resistant isolates do not

have mutations in any of the above genes, suggesting alternative mechanisms of INH resistance (Karakousis 2009).

3.2 Rifampin and other rifamycins

The rifamycins were first isolated in 1957 from *Amycolatopsis* (formerly *Streptomyces*) *mediterranei* as part of an Italian antibiotic screening program (Sensi 1983). Their incorporation into the standard anti-tuberculosis regimen allowed reduction of the duration of treatment from 18 to 9 months. Although the early bactericidal activity of the rifamycins is inferior to that of INH, the former are the most potent sterilizing agents available in TB chemotherapy, continuing to kill persistent tubercle bacilli throughout the duration of therapy (Mitchison 1985; Grosset, Lounis et al. 1998). Rifampin is a broad-spectrum antibiotic and the most widely used rifamycin to treat TB.



Rifampicin

3.2.1 Mechanism of action

Rifamycins contain an aromatic nucleus linked on both sides by an aliphatic bridge. The rifamycins easily diffuse across the *M. tuberculosis* cell membrane due to their lipophilic profile (Wade and Zhang 2004). Their bactericidal activity has been attributed to their ability to inhibit transcription by binding with high affinity to bacterial DNA-dependent RNA polymerase. Although the molecular target of rifampin has been well characterized, the precise mechanism by which this interaction leads to mycobacterial killing remains unclear.

3.2.2 Mechanism of resistance


Although INH monoresistance is relatively common in *M. tuberculosis*, resistance to rifampin alone is rare, and more than 90% of rifampin-resistant isolates are also resistant to INH. Therefore, rifampin resistance has been used as a surrogate marker for MDR-TB. Resistance to rifampin in *M. tuberculosis* arises at a frequency of 10^{-7} to 10^{-8} organisms, most commonly as single point mutations in the *rpoB* gene, which encodes the β -subunit of RNA polymerase (Telenti, Imboden et al. 1993). In over 90% of rifampin-resistant clinical isolates, point mutations cluster in an 81-base pair "hot-spot" region between codons 507 and 533 of the *rpoB* gene, with mutations in codons 531 [Ser] and 526 [His] predominating (Ramaswamy and Musser 1998). However, a small percentage of rifampin-resistant isolates

(<5%) do not contain any mutations in the *rpoB* gene, suggesting alternative resistance mechanisms, potentially including altered rifampin permeability or mutations in other RNA polymerase subunits (Musser 1995).

Higher doses of the rifamycins, especially rifapentine, have the potential to further shorten the duration of TB treatment. Therefore, there is renewed interest in establishing the maximally tolerated dose of these drugs, and a number of clinical trials are planned or underway to examine the safety, pharmacokinetics and efficacy of higher than standard doses of rifampicin or rifapentine in first-line TB treatment (Ginsberg 2010).

3.3 Pyrazinamide

Since the discovery of pyrazinamide (PZA) in 1952 (Yeager, Munroe et al. 1952), and its routine use to treat TB, the duration of treatment required to achieve acceptable relapse rates has been reduced from 9–12 months to the current 6 months (Steele and Des Prez 1988). Although its bactericidal activity is inferior to that of INH and rifampin (Jindani, Aber et al. 1980), the potent sterilizing activity and treatment-shortening potential of PZA has been attributed to the drug's unique ability to target semi-dormant populations of bacilli residing within an acidic environment (Mitchison 1985).



Pyrazinamide

3.3.1 Mechanism of action

PZA is an amide derivative of pyrazine-2-carboxylic acid and nicotinamide analog. Despite recognition of its anti-tuberculosis activity six decades ago, the mechanism of action of PZA remains poorly understood. PZA has been hypothesized to act against bacilli residing in acidified compartments of the lung that are present during the early inflammatory stages of infection (Mitchison 1985), since the drug's sterilizing activity appears to be limited to the first 2 months of therapy (1986; 1986; 1991). PZA enters tubercle bacilli passively and via an ATP-dependent transport system (Raynaud, Laneelle et al. 1999). Intracellular accumulation of the drug occurs because of an inefficient efflux system unique to *M. tuberculosis*. PZA, like INH, is a pro-drug, requiring activation to its active form, pyrazinoic acid (POA), by the enzyme pyrazinamidase (PZase) (Konno, Feldmann et al. 1967; Scorpio and Zhang 1996). Uptake and intrabacillary accumulation of POA is enhanced when the extracellular pH is acidic (Zhang, Scorpio et al. 1999). The anti-tuberculosis activity of PZA has been attributed to disruption of the proton motive force required for essential membrane transport functions by POA at acidic pH (Zhang, Wade et al. 2003), although investigation into potential specific cellular targets is ongoing.


3.3.2 Mechanism of resistance

PZA resistance has been attributed primarily to mutations in the *pncA* gene encoding PZase (Scorpio and Zhang 1996). Most mutations, including point mutations, deletions, and insertions, have been reported in a 561-bp region of the open reading frame or in an 82-bp region of its putative promoter (Scorpio, Lindholm-Levy et al. 1997; Jureen, Werngren et al. 2008). The relatively high degree of diversity in *pncA* mutations among PZA-resistant clinical isolates has complicated the development of molecular assays for the rapid and economical detection of PZA resistance. A small percentage of isolates with high-level PZA resistance contain no mutations in *pncA* or its promoter, suggesting alternative mechanisms of resistance such as deficient uptake (Raynaud, Laneelle et al. 1999), enhanced efflux, or altered *pncA* regulation.

The high specificity of PZA for *M. tuberculosis*, with little or no activity against *M. bovis* and other mycobacteria, is attributable to *pncA* mutations, which render PZase inactive in the latter mycobacterial species.

3.4 Ethambutol

Ethambutol (EMB; dextro-2,2'-(ethylenediimino)-di-1-butanol) was initially reported to have anti-tuberculosis activity in 1961 and, together with INH, rifampin, and PZA, constitutes the modern-day short-course for the treatment of drug-susceptible TB. Like INH, EMB primarily kills actively multiplying bacilli and has very poor sterilizing activity.



Ethambutol

3.4.1 Mechanism of action

The primary pathway affected by EMB appears to be that of arabinogalactan biosynthesis through inhibition of cell wall arabinan polymerization (Mikusova, Slayden et al. 1995). EMB also has been reported to inhibit several other cellular pathways, including RNA metabolism (Forbes, Kuck et al. 1962; Forbes, Kuck et al. 1965), transfer of mycolic acids into the cell wall (Takayama, Armstrong et al. 1979), phospholipid synthesis (Cheema and Khuller 1985; Cheema and Khuller 1985), and spermidine biosynthesis (Paulin, Brander et al. 1985).


3.4.2 Mechanism of resistance

Resistance to EMB in *M. tuberculosis* is usually associated with point mutations in the *embCAB* operon (Belanger, Besra et al. 1996). Genetic and biochemical studies have shown that the EmbA and EmbB proteins are involved in the formation of the proper terminal hexaarabinofuranoside motif during arabinogalactan synthesis (Escuyer, Lety et al. 2001),

while EmbC is involved in lipoarabinomannan synthesis (Zhang, Torrelles et al. 2003). As the majority of EMB-resistant clinical isolates contain mutations in the *embB* gene (Sreevatsan, Stockbauer et al. 1997; Telenti, Philipp et al. 1997; Ramaswamy, Amin et al. 2000), EmbB is considered to be the main target of EMB, although X-ray crystallographic data supporting this interaction are lacking. More recently, the most commonly observed mutations in *embB* codon 306 have been reported to be associated with variable degrees of EMB resistance, indicating that such mutations may be necessary but not sufficient for high-level EMB resistance. Other potential mutations involved in EMB resistance include a Gln379Arg substitution in *M. tuberculosis embR*, as well as mutations in the *rmlD*, *rmlA2*, and *Rv0340* genes. As many as one quarter of all EMB-resistant *M. tuberculosis* isolates do not harbor mutations in any of the genes described above, suggesting alternative mechanisms of EMB resistance (Karakousis 2009).

3.5 Aminoglycosides

The discovery of streptomycin in the early 1940s represented the first breakthrough in TB chemotherapy. Although relapse rates are comparable when streptomycin is substituted for EMB as the fourth drug in addition to INH, rifampin, and PZA, the poor oral absorption of streptomycin, which necessitates parenteral administration, as well as the toxicity profile of the aminoglycosides, have favored the use of EMB in first-line anti-tuberculosis therapy. Other aminoglycosides with significant antimycobacterial activity include kanamycin and amikacin. Aminoglycosides are used currently as second-line drugs primarily in the treatment of MDR-TB.



Streptomycin

3.5.1 Mechanism of action

As in other bacteria, the mode of action of the aminoglycosides against mycobacterial species is through their binding to the 30S ribosomal subunit, which affects polypeptide synthesis, ultimately resulting in inhibition of translation.


3.5.2 Mechanism of resistance

Resistance to streptomycin and the other aminoglycosides in *M. tuberculosis* usually develops by mutation of the ribosome target binding sites. Interestingly, although cross-resistance is observed between amikacin and kanamycin (Allen, Mitchison et al. 1983), these drugs are not cross-resistant with streptomycin (Tsukamura and Mizuno 1975), suggesting

distinct mechanisms of resistance. Mutations in the *rpsL* gene, which encodes the ribosomal protein S12, account for approximately half of all streptomycin-resistant clinical isolates (Nair, Rouse et al. 1993; Cooksey, Morlock et al. 1996), with the K43R mutation predominating. In about 20% of streptomycin-resistant *M. tuberculosis* clinical isolates, such resistance is associated with mutations in the *rrs* gene, which are usually clustered in the regions surrounding nucleotides 530 or 912 (Douglass and Steyn 1993; Cooksey, Morlock et al. 1996). The particular vulnerability of *rrs* to mutation, leading to streptomycin resistance in *M. tuberculosis* and other slow-growing mycobacteria, can be explained by the fact that these mycobacterial species, unlike other bacteria, contain only a single copy of the *rrs* gene. Generally, mutations in the *rpsL* and *rrs* genes confer high-level (MIC > 1,000 mg/L) or intermediate-level (MIC = 64–512 mg/L) resistance to streptomycin (Sreevatsan, Pan et al. 1996). On the other hand, mechanisms of low-level resistance to streptomycin (MIC = 4–32 mg/L) remain largely undefined but may be attributable to changes in cell envelope permeability or diminished drug uptake (Honore and Cole 1994; Cooksey, Morlock et al. 1996). More recently, it has been shown that mutations in *gidB*, which encodes a conserved S-adenosylmethionine-dependent 16S rRNA methyltransferase, can confer low-level resistance to streptomycin (Wong, Lee et al. 2011).

3.6 Fluoroquinolones

The fluoroquinolones (moxifloxacin, gatifloxacin, sparfloxacin, levofloxacin, ofloxacin, and ciprofloxacin), are bactericidal antibiotics with excellent activity against *M. tuberculosis* and are currently used as second-line drugs in TB treatment. New-generation fluoroquinolones [moxifloxacin, gatifloxacin] are under clinical evaluation as first-line antibiotics with the goal of shortening the duration of TB treatment.



3.6.1 Mechanism of action


Fluoroquinolones exert their powerful antibacterial activity by trapping gyrase and topoisomerase IV on DNA as ternary complexes, thereby blocking the movement of replication forks and transcription complexes (Drlica and Malik 2003). Unlike most other bacterial species, *M. tuberculosis* lacks topoisomerase IV, but contains the genes *gyrA* and *gyrB* encoding the A and B subunits, respectively, of DNA gyrase (Cole, Brosch et al. 1998).

3.6.2 Mechanism of resistance

Fluoroquinolone resistance in *M. tuberculosis* is most commonly associated with mutations in the conserved quinolone resistance-determining region (QRDR) of *gyrA* and *gyrB* involved in the interaction between the drug and DNA gyrase (Ginsburg, Grosset et al. 2003). The degree of fluoroquinolone resistance is dictated by the specific amino acid

3.8 Ethionamide


Ethionamide, a synthetic compound structurally related to INH, is a pro-drug, requiring activation by the monooxygenase EthA (Baulard, Betts et al. 2000; DeBarber, Mdluli et al. 2000; Vannelli, Dykman et al. 2002). Similar to INH, ethionamide inhibits mycolic acid synthesis by binding the ACP reductase InhA. Approximately three-quarters of *M. tuberculosis* isolates with high-level ethionamide resistance (MIC > 50 mg/L) have mutations in *ethA* or *inhA* (Morlock, Metchock et al. 2003). Recently, other potential mechanisms of resistance have been identified, as *M. tuberculosis mshA* deletion mutants were found to be defective in mycothiol biosynthesis and resistant to ethionamide, likely due to defective activation of the drug (Vilcheze, Av-Gay et al. 2008).



Ethionamide

3.9 Capreomycin


Capreomycin is a macrocyclic polypeptide antibiotic isolated from *Streptomyces capreolus* (Karakousis 2009). Capreomycin, like streptomycin and kanamycin, inhibits protein synthesis through modification of ribosomal structures at the 16S rRNA (Wade and Zhang 2004). Recent studies using site-directed mutagenesis have identified the binding site of capreomycin on 16S rRNA helix 44 (Akbergenov, Shcherbakov et al. 2011). In *M. tuberculosis*, resistance to capreomycin and kanamycin has been associated with mutations in the *rrs* gene encoding 16S rRNA (Taniguchi, Chang et al. 1997; Alangaden, Kreiswirth et al. 1998). Mutations in the gene *tlyA* encoding a 2'-O-methyltransferase of 16S rRNA and 23S rRNA have been implicated in resistance to capreomycin and viomycin (Johansen, Maus et al. 2006), and such resistance is generally associated with the addition of methyl groups to rRNA rather than their loss (Sander, Meier et al. 1996). However, recent studies have shown that capreomycin-resistant strains lack mutations in *tlyA* (Jugheli, Bzekalava et al. 2009).



Capreomycin

3.10 Cycloserine


Cycloserine is a d-alanine analogue, which interrupts peptidoglycan synthesis by inhibiting the enzymes d-alanine racemase (AlrA) and d-alanine:d-alanine ligase (Ddl) (Caceres, Harris et al. 1997). Overexpression of *M. tuberculosis* AlrA and Ddl on a multicopy vector results in resistance to D-cycloserine in *M. smegmatis* and *M. bovis* BCG (Caceres, Harris et al. 1997; Feng and Barletta 2003), although whether similar mechanisms are responsible for cycloserine resistance in *M. tuberculosis* remain to be determined.



Cycloserine

3.11 Paraaminosalicylic acid

Paraaminosalicylic acid (PAS) is thought to inhibit folic acid biosynthesis and uptake of iron (Wade and Zhang 2004). Mutations in the *thyA* gene encoding the enzyme thymidylate synthase of the folate biosynthesis pathway have been identified in PAS-resistant *M. tuberculosis* clinical isolates, suggesting that PAS may act as a folate antagonist (Rengarajan, Sassetti et al. 2004). However, only slightly more than a third of the evaluated PAS-resistant strains had mutations in *thyA*, suggesting the existence of additional mechanisms of PAS resistance. Thr202Ala has been reported as the most common mutation associated with PAS resistance, although this mutation has also been identified in several PAS-susceptible isolates (Leung, Yip et al. 2010).



Paraaminosalicylic acid

4. New TB drugs


Several new drugs have emerged recently as potential candidates for the treatment of TB. In most cases, their mechanism of action is distinct from that of the classical anti-TB drugs, although strains resistant to several of the novel drugs already have been described even prior to their routine clinical use.

4.1 Nitroimidazoles

Reduced oxygen tension may be an important microenvironmental condition encountered by persistent bacilli within necrotic lung granulomas in the human host (Haapanen, Kass et al. 1959). Interestingly, although *in vitro* exposure to microaerophilic conditions renders *M. tuberculosis* less susceptible to killing by INH and rifampin, the bacilli become susceptible to metronidazole (Wayne and Sramek 1994; Wayne and Hayes 1996) a nitroimidazole drug used to treat anaerobic infections. Metronidazole, which becomes reductively activated by the pyruvate:ferredoxin oxidoreductase system under anoxic conditions (Edwards 1993) lacks antituberculous activity in mouse models (Brooks, Furney et al. 1999; Klinkenberg, Sutherland et al. 2008) and in guinea pigs (Hoff, Caraway et al. 2008), but displays activity in *M. tuberculosis*-infected rabbits (Via, Lin et al. 2008). Clinical studies evaluating the activity of metronidazole against MDR-TB are ongoing.

4.1.1 PA-824

PA-824, a small molecule nitroimidazopyran related to metronidazole, exhibits bactericidal activity against actively multiplying and stationary-phase cultures of *M. tuberculosis*, as well as in murine and guinea pig models of TB infection (Stover, Warrener et al. 2000; Lenaerts, Gruppo et al. 2005). In addition, PA-824 is highly active against multidrug-resistant clinical isolates of *M. tuberculosis* (MIC < 1 µg/mL), suggesting no cross-resistance with current anti-tuberculosis drugs (Lenaerts, Gruppo et al. 2005). Like metronidazole, PA-824 is a pro-drug requiring reductive activation of an aromatic nitro group, which involves an F420-dependent glucose-6-phosphate dehydrogenase encoded by Rv0407 (*fgd1*) (Stover, Warrener et al. 2000) and deazaflavin-dependent nitroreductase (Ddn) encoded by Rv3547 (Singh, Manjunatha et al. 2008), in order to exert its antitubercular effect. The activity of PA-824 is at least partially mediated through inhibition of the oxidation of hydroxymycolates to ketomycolates, a terminal step in mycolic acid synthesis (Stover, Warrener et al. 2000). Recently, formation of the des-nitroimidazole metabolite of PA-824 was shown to generate reactive nitrogen species, including nitric oxide, which appears to contribute to the killing activity of PA-824 and may explain the activity of the drug against non-replicating bacilli (Singh, Manjunatha et al. 2008). Similar to INH, resistance to PA-824 is most commonly mediated by mutations that lead to loss of pro-drug activation, including those in the genes Rv0407 and Rv3547 encoding the activating enzymes.




PA-824

4.1.2 OPC-67683

OPC-67683 is a nitro-dihydro-imidazooxazole derivative with potent activity against drug-susceptible *M. tuberculosis* and MDR-TB. The drug exerts its killing activity by inhibiting the synthesis of methoxy- and keto-mycolic acids. The substitution of OPC-67683 for INH and


EMB in the standard regimen alongside rifampin and PZA led to more rapid sterilization of *M. tuberculosis*-infected mouse lungs (Matsumoto, Hashizume et al. 2006). Like the other nitroimidazoles, OPC-67683 is a pro-drug requiring reductive activation by *M. tuberculosis*. As in the case of PA-824, mutations in the Rv3547 gene have been identified in strains resistant to OPC-67683, indicating defective drug activation (Matsumoto, Hashizume et al. 2006).



OPC-67683

4.2 TMC207

TMC207 (also named R207910 or “J compound”) is a first-in-class anti-TB diarylquinoline with bactericidal and sterilizing activities against drug-susceptible and drug-resistant *M. tuberculosis in vitro* and in animal models, including in a murine model of latent TB infection (Zhang, Li et al. 2011). Mouse model studies suggest a synergistic relationship between TMC207 and PZA (Matteelli, Carvalho et al. 2010). TMC207 inhibits ATP synthase, a critical enzyme in the synthesis of ATP for *M. tuberculosis* (Andries, Verhasselt et al. 2005). The addition of TMC207 to standard therapy for MDR-TB significantly reduced the time to conversion to a negative sputum culture and increased the proportion of patients with conversion of sputum culture as compared with placebo (Diacon, Pym et al. 2009). Resistance to TMC207 is mediated by mutations in the *atpE* gene encoding the transmembrane and oligomeric C subunit of ATP synthase, typically at positions 63 or 66 (Petrella, Cambau et al. 2006). However, more recent studies have shown that a majority of *in vitro*-generated mutants resistant to TMC207 lacked mutations in *atpE*, indicating alternative mechanisms of drug resistance (Huitric, Verhasselt et al. 2010).




TMC207

4.3 SQ109

SQ109 was identified by screening a large synthesized combinatorial library based on the 1,2-ethylenediamine structure of EMB, and was found to have limited toxicity and potent


activity against intracellular bacilli as well as in a murine model of chronic TB infection (Protopopova, Hanrahan et al. 2005). Early clinical data reveal the drug's potential to enhance the treatment of TB during the first 2 months of intensive therapy and also to treat MDR-TB (Laloo and Ambaram 2010). Whether upregulation of *ahpC* expression, observed in strains resistant to INH, EMB, and SQ109, plays a role in resistance to SQ109 or merely reflects a compensatory metabolic mechanism remains to be determined (Jia, Coward et al. 2005).



SQ109

4.4 Phenothiazines

The antipsychotic phenothiazine drug thioridazine has been reported to be active against drug-susceptible and drug-resistant *M. tuberculosis*, both in macrophages (Ordway, Viveiros et al. 2003) as well as in murine models (van Soolingen, Hernandez-Pando et al. 2010). Although serum concentrations above the MIC for *M. tuberculosis* (8-16 mg/L range) cannot be safely attained in humans, thioridazine still has potential as an antimycobacterial drug because of intracellular accumulation, such that concentrations inside macrophages are at least 10-fold higher than in serum. Despite the favorable toxicity profile of thioridazine relative to chlorpromazine and other phenothiazines, cardiac arrhythmia associated with prolongation of the QTc interval remains a risk. Thioridazine has been used successfully to cure patients with XDR-TB in Argentina and as salvage therapy in similar patients in India (Amaral, Boeree et al. 2010). The mechanism of action of thioridazine is likely multifactorial, as the drug appears to act on enzymes involved in fatty acid metabolism and membrane proteins, particularly efflux pumps (Dutta, Mazumdar et al. 2011), in addition to inhibiting type II NADH:menaquinone oxidoreductase as a phenothiazine (Weinstein, Yano et al. 2005). Mechanisms of *M. tuberculosis* resistance to the phenothiazines remain to be elucidated.



Thioridazine

4.5 Oxazolidinones

Oxazolidinones are a new chemical class of synthetic antibiotics related to cycloserine with broad-spectrum activity against gram-positive pathogens through inhibition of protein synthesis.

4.5.1 Linezolid

Linezolid is the first compound belonging to the oxazolidinone class approved for clinical use. Due to its ability to penetrate macrophages, linezolid is active against intracellular bacilli, exerting its activity by binding to the ribosomal 50S subunit and thus inhibiting an early step in protein synthesis (Zhang 2005). Linezolid is most commonly used to treat drug-resistant TB, but its use has been limited by toxicity concerns, particularly hematological disturbances such as leukopenia and thrombocytopenia, as well as peripheral neuropathy, which may be irreversible. While resistance to linezolid in *M. tuberculosis* clinical isolates is rarely reported, *in vitro*-selected mutants with high-level resistance to linezolid (MIC = 16–32 mg/L) have been found to contain mutations at G2061T and G2576T in the 23S rRNA gene (Hillemann, Rusch-Gerdes et al. 2008). On the other hand, mutants with lower level linezolid resistance (MIC = 4–8 mg/L) lack mutations in the 23S rRNA gene, implicating other possible mechanisms of resistance.



Linezolid

4.5.2 PNU-100480

PNU-100480, another oxazolidinone, has been shown to have more potent activity against *M. tuberculosis* than linezolid, as the MIC of PNU100480 is half that of linezolid, and is as bactericidal as isoniazid in an acute model of TB infection in mice (Cynamon, Klemens et al. 1999). Recent studies in the mouse model have shown that the addition of PNU-100480 to the standard first-line regimen of rifampin, INH, and PZA can shorten the duration of treatment necessary to prevent relapse (Williams, Brickner et al. 2009), suggesting that this drug may have sterilizing activity against drug-susceptible and drug-resistant *M. tuberculosis*. Recent Phase I studies have shown that PNU-100480 is safe and well tolerated at all tested doses, and exhibits synergy with PZA in an ex vivo whole-blood culture assay (Wallis, Jakubiec et al. 2011). Resistance mechanisms are expected to be similar to those of linezolid.

4.5.3 AZD5847

AZD5847 was originally designed for treatment of gram-positive infections, but was later repositioned for TB treatment with the goal of improving the toxicity profile associated with linezolid, including inhibition of mitochondrial protein synthesis, thrombocytopenia, and myelosuppression (Koul, Arnoult et al. 2011). Like linezolid, AZD5847 has bactericidal activity against *M. tuberculosis* in macrophages, as well as in murine models of acute and chronic TB infection. Recent Phase I trials revealed that oral administration of the drug up to 800 mg twice daily for 14 days was satisfactorily tolerated in healthy volunteers. Although

bioavailability decreases with increasing dose, this effect may be largely compensated if taken within 2 hours of meals, and the exposures achieved in man correspond to efficacious exposures in the mouse model of TB infection (B. Subramanian, Gordon Research Conference on Tuberculosis Drug Development, July 2011). Phase 2 studies to be conducted in South Africa are in the planning stage.

4.6 Benzothiazinones

The 1,3-benzothiazin-4-ones (BTZs) represent a new class of drugs, which have activity against *M. tuberculosis* *in vitro*, *ex vivo*, and in murine TB models (Makarov, Manina et al. 2009). BTZs are activated in *M. tuberculosis* by reduction of an essential nitro group to a nitroso derivative, which then specifically reacts with a cysteine residue in the active site of the enzyme decaprenylphosphoryl- β -D-ribose 2'-epimerase (DprE1) (Trefzer, Rengifo-Gonzalez et al. 2010). Inhibition of this enzymatic activity abolishes the formation of decaprenylphosphoryl arabinose, a key precursor that is required for the synthesis of the cell-wall arabinans, thus causing bacterial lysis and death (Makarov, Manina et al. 2009). Although spontaneous BTZ-resistant laboratory mutants were found to have a Ser or Gly substitution at codon Cys387 of *dprE1*, resistance to BTZs has not been reported in clinical *M. tuberculosis* isolates (Pasca, Degiacomi et al. 2010). Recently, a novel resistance mechanism to BTZ was described in *M. smegmatis* involving the overexpression of the nitroreductase NfnB, which leads to the inactivation of the drug by reduction of a critical nitro-group to an amino-group (Manina, Bellinzoni et al. 2010). However, *M. tuberculosis* seems to lack nitroreductases able to inactivate BTZs.

5. Antibiotic tolerance

Antibiotic tolerance refers to the ability of nonreplicating bacteria to resist killing by cell wall-active antibiotics, which target actively multiplying organisms (Tomasz, Albino et al. 1970). This phenomenon is distinct from drug resistance (intrinsic or acquired), since it is not attributable to genetic mutations, and the organisms regain susceptibility to these antibiotics once the stress conditions have been removed and bacterial growth resumes. The prolonged duration of antibiotic treatment required to eradicate TB is believed to reflect the altered physiological state of “persistent” bacilli, which have developed tolerance to standard anti-tuberculosis drugs, particularly to isoniazid, which inhibits mycolic acid synthesis (Karakousis, Williams et al. 2008). One of the major challenges facing current TB drug development programs is to identify compounds with sterilizing activity against antibiotic tolerant “persisters”, with the ultimate goal of shortening the duration of TB treatment.

6. Conclusion

The principal etiology of drug-resistant TB remains inadequate and/or incomplete treatment, including poor medical adherence to the standard treatment regimen and the addition of a single active drug to a failing drug regimen (Sharma and Mohan 2006). Given the increasing global prevalence of drug-resistant TB, it is of paramount importance to understand the mode of action of each drug as well as the molecular basis of drug resistance. Novel anti-TB drugs, which are safe, able to shorten the course of treatment,

effective against drug-resistant strains and latent TB infection, are urgently needed, especially in the era of MDR- and XDR-TB.

7. References

- (1986). "Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. East and Central African/British Medical Research Council Fifth Collaborative Study." *Tubercle* 67(1): 5-15.
- (1986). "Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council." *Am Rev Respir Dis* 133(5): 779-783.
- (1991). "Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council." *Am Rev Respir Dis* 143(4 Pt 1): 700-706.
- Abate, G., S. E. Hoffner, et al. (2001). "Characterization of isoniazid-resistant strains of *Mycobacterium tuberculosis* on the basis of phenotypic properties and mutations in *katG*." *Eur J Clin Microbiol Infect Dis* 20(5): 329-333.
- Akbergenov, R., D. Shcherbakov, et al. (2011). "Molecular basis for the selectivity of antituberculosis compounds capreomycin and viomycin." *Antimicrob Agents Chemother*.
- Alangaden, G. J., B. N. Kreiswirth, et al. (1998). "Mechanism of resistance to amikacin and kanamycin in *Mycobacterium tuberculosis*." *Antimicrob Agents Chemother* 42(5): 1295-1297.
- Allen, B. W., D. A. Mitchison, et al. (1983). "Amikacin in the treatment of pulmonary tuberculosis." *Tubercle* 64(2): 111-118.
- Amaral, L., M. J. Boeree, et al. (2010). "Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!" *Int J Antimicrob Agents* 35(6): 524-526.
- Andini, N. and K. A. Nash (2006). "Intrinsic macrolide resistance of the *Mycobacterium tuberculosis* complex is inducible." *Antimicrob Agents Chemother* 50(7): 2560-2562.
- Andries, K., P. Verhasselt, et al. (2005). "A diarylquinoline drug active on the ATP synthase of *Mycobacterium tuberculosis*." *Science* 307(5707): 223-227.
- Aubry, A., N. Veziris, et al. (2006). "Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of *Mycobacterium tuberculosis*: functional analysis of mutant enzymes." *Antimicrob Agents Chemother* 50(1): 104-112.
- Banerjee, A., E. Dubnau, et al. (1994). "*inhA*, a gene encoding a target for isoniazid and ethionamide in *Mycobacterium tuberculosis*." *Science* 263(5144): 227-230.
- Bardou, F., C. Raynaud, et al. (1998). "Mechanism of isoniazid uptake in *Mycobacterium tuberculosis*." *Microbiology* 144 (Pt 9): 2539-2544.
- Basso, L. A., R. Zheng, et al. (1998). "Mechanisms of isoniazid resistance in *Mycobacterium tuberculosis*: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates." *Journal of Infectious Diseases* 178(3): 769-775.

- Baulard, A. R., J. C. Betts, et al. (2000). "Activation of the pro-drug ethionamide is regulated in mycobacteria." *J Biol Chem* 275(36): 28326-28331.
- Bekierkunst, A. (1966). "Nicotinamide-adenine dinucleotide in tubercle bacilli exposed to isoniazid." *Science* 152(721): 525-526.
- Belanger, A. E., G. S. Besra, et al. (1996). "The embAB genes of *Mycobacterium avium* encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol." *Proc Natl Acad Sci U S A* 93(21): 11919-11924.
- Bermudez, L. E. and Y. Yamazaki (2004). "Effects of macrolides and ketolides on mycobacterial infections." *Curr Pharm Des* 10(26): 3221-3228.
- Brennan, P. J., S. A. Rooney, et al. (1970). "The lipids of *Mycobacterium tuberculosis* BCG: fractionation, composition, turnover and the effects of isoniazid." *Ir J Med Sci* 3(8): 371-390.
- Brooks, J. V., S. K. Furney, et al. (1999). "Metronidazole therapy in mice infected with tuberculosis." *Antimicrob Agents Chemother* 43(5): 1285-1288.
- Buriankova, K., F. Doucet-Populaire, et al. (2004). "Molecular basis of intrinsic macrolide resistance in the *Mycobacterium tuberculosis* complex." *Antimicrob Agents Chemother* 48(1): 143-150.
- Caceres, N. E., N. B. Harris, et al. (1997). "Overexpression of the D-alanine racemase gene confers resistance to D-cycloserine in *Mycobacterium smegmatis*." *Journal of Bacteriology* 179(16): 5046-5055.
- Canetti, G. (1965). "Present aspects of bacterial resistance in tuberculosis." *Am Rev Respir Dis* 92(5): 687-703.
- Cheema, S. and G. K. Khuller (1985). "Metabolism of phospholipids in *Mycobacterium smegmatis* ATCC 607 in the presence of ethambutol." *Indian J Med Res* 82: 207-213.
- Cheema, S. and G. K. Khuller (1985). "Phospholipid composition and ethambutol sensitivity of *Mycobacterium smegmatis* ATCC 607." *Indian J Exp Biol* 23(9): 511-513.
- Cole, S. T., R. Brosch, et al. (1998). "Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence." *Nature* 393(6685): 537-544.
- Cooksey, R. C., G. P. Morlock, et al. (1996). "Characterization of streptomycin resistance mechanisms among *Mycobacterium tuberculosis* isolates from patients in New York City." *Antimicrob Agents Chemother* 40(5): 1186-1188.
- Cynamon, M. H., S. P. Klemens, et al. (1999). "Activities of several novel oxazolidinones against *Mycobacterium tuberculosis* in a murine model." *Antimicrob Agents Chemother* 43(5): 1189-1191.
- DeBarber, A. E., K. Mdluli, et al. (2000). "Ethionamide activation and sensitivity in multidrug-resistant *Mycobacterium tuberculosis*." *Proc Natl Acad Sci U S A* 97(17): 9677-9682.
- Dessen, A., A. Quemard, et al. (1995). "Crystal structure and function of the isoniazid target of *Mycobacterium tuberculosis*." *Science* 267(5204): 1638-1641.
- Diacon, A. H., A. Pym, et al. (2009). "The diarylquinoline TMC207 for multidrug-resistant tuberculosis." *N Engl J Med* 360(23): 2397-2405.
- Douglass, J. and L. M. Steyn (1993). "A ribosomal gene mutation in streptomycin-resistant *Mycobacterium tuberculosis* isolates." *Journal of Infectious Diseases* 167(6): 1505-1506.

- Drlica, K. and M. Malik (2003). "Fluoroquinolones: action and resistance." *Curr Top Med Chem* 3(3): 249-282.
- Dutta, N. K., K. Mazumdar, et al. (2011). "New patentable use of an old neuroleptic compound thioridazine to combat tuberculosis: a gene regulation perspective." *Recent Pat Antiinfect Drug Discov* 6(2): 128-138.
- Edwards, D. I. (1993). "Nitroimidazole drugs--action and resistance mechanisms. I. Mechanisms of action." *J Antimicrob Chemother* 31(1): 9-20.
- Escuyer, V. E., M. A. Lety, et al. (2001). "The role of the embA and embB gene products in the biosynthesis of the terminal hexaarabinofuranosyl motif of *Mycobacterium smegmatis* arabinogalactan." *J Biol Chem* 276(52): 48854-48862.
- Feng, Z. and R. G. Barletta (2003). "Roles of *Mycobacterium smegmatis* D-alanine:D-alanine ligase and D-alanine racemase in the mechanisms of action of and resistance to the peptidoglycan inhibitor D-cycloserine." *Antimicrob Agents Chemother* 47(1): 283-291.
- Forbes, M., N. A. Kuck, et al. (1962). "Mode of action of ethambutol." *Journal of Bacteriology* 84: 1099-1103.
- Forbes, M., N. A. Kuck, et al. (1965). "Effect of Ethambutol on Nucleic Acid Metabolism in *Mycobacterium Smegmatis* and Its Reversal by Polyamines and Divalent Cations." *Journal of Bacteriology* 89: 1299-1305.
- Gangadharan, P. R., F. M. Harold, et al. (1963). "Selective inhibition of nucleic acid synthesis in *Mycobacterium tuberculosis* by isoniazid." *Nature* 198: 712-714.
- Ginsberg, A. M. (2010). "Drugs in development for tuberculosis." *Drugs* 70(17): 2201-2214.
- Ginsburg, A. S., J. H. Grosset, et al. (2003). "Fluoroquinolones, tuberculosis, and resistance." *Lancet Infectious Diseases* 3(7): 432-442.
- Grosset, J., N. Lounis, et al. (1998). "Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice." *Am J Respir Crit Care Med* 157(5 Pt 1): 1436-1440.
- Haapanen, J. H., I. Kass, et al. (1959). "Studies on the gaseous content of tuberculous cavities." *Am Rev Respir Dis* 80(1, Part 1): 1-5.
- Hillemann, D., S. Rusch-Gerdes, et al. (2008). "In vitro-selected linezolid-resistant *Mycobacterium tuberculosis* mutants." *Antimicrob Agents Chemother* 52(2): 800-801.
- Hoff, D. R., M. L. Caraway, et al. (2008). "Metronidazole lacks antibacterial activity in guinea pigs infected with *Mycobacterium tuberculosis*." *Antimicrob Agents Chemother* 52(11): 4137-4140.
- Honore, N. and S. T. Cole (1994). "Streptomycin resistance in mycobacteria." *Antimicrob Agents Chemother* 38(2): 238-242.
- Huitric, E., P. Verhasselt, et al. (2010). "Rates and mechanisms of resistance development in *Mycobacterium tuberculosis* to a novel diarylquinoline ATP synthase inhibitor." *Antimicrob Agents Chemother* 54(3): 1022-1028.
- Jia, L., L. Coward, et al. (2005). "Pharmacoproteomic effects of isoniazid, ethambutol, and N-geranyl-N'-(2-Adamantyl)ethane-1,2-diamine (SQ109) on *Mycobacterium tuberculosis* H37Rv." *J Pharmacol Exp Ther* 315(2): 905-911.
- Jindani, A., V. R. Aber, et al. (1980). "The early bactericidal activity of drugs in patients with pulmonary tuberculosis." *Am Rev Respir Dis* 121(6): 939-949.


- Johansen, S. K., C. E. Maus, et al. (2006). "Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2'-O-methylations in 16S and 23S rRNAs." *Mol Cell* 23(2): 173-182.
- Jugheli, L., N. Bzekalava, et al. (2009). "High level of cross-resistance between kanamycin, amikacin, and capreomycin among *Mycobacterium tuberculosis* isolates from Georgia and a close relation with mutations in the *rrs* gene." *Antimicrob Agents Chemother* 53(12): 5064-5068.
- Jureen, P., J. Werngren, et al. (2008). "Pyrazinamide resistance and *pncA* gene mutations in *Mycobacterium tuberculosis*." *Antimicrob Agents Chemother* 52(5): 1852-1854.
- Karakousis, P. C. (2009). Mechanisms of Action and Resistance of Antimycobacterial Agents. In: *Antimicrobial Drug Resistance*. D. L. Mayers, Springer: pp.271-291.
- Karakousis, P. C., W. R. Bishai, et al. (2004). "Mycobacterium tuberculosis cell envelope lipids and the host immune response." *Cell Microbiol* 6(2): 105-116.
- Karakousis, P. C., E. P. Williams, et al. (2008). "Altered expression of isoniazid-regulated genes in drug-treated dormant *Mycobacterium tuberculosis*." *J Antimicrob Chemother* 61(2): 323-331.
- Klinkenberg, L. G., L. A. Sutherland, et al. (2008). "Metronidazole lacks activity against *Mycobacterium tuberculosis* in an in vivo hypoxic granuloma model of latency." *Journal of Infectious Diseases* 198(2): 275-283.
- Kocagoz, T., C. J. Hackbarth, et al. (1996). "Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of *Mycobacterium tuberculosis* H37Ra." *Antimicrob Agents Chemother* 40(8): 1768-1774.
- Kochi, A., B. Vareldzis, et al. (1993). "Multidrug-resistant tuberculosis and its control." *Res Microbiol* 144(2): 104-110.
- Konno, K., F. M. Feldmann, et al. (1967). "Pyrazinamide susceptibility and amidase activity of tubercle bacilli." *Am Rev Respir Dis* 95(3): 461-469.
- Koul, A., E. Arnoult, et al. (2011). "The challenge of new drug discovery for tuberculosis." *Nature* 469(7331): 483-490.
- Laloo, U. G. and A. Ambaram (2010). "New antituberculous drugs in development." *Curr HIV/AIDS Rep* 7(3): 143-151.
- Lee, A. S., A. S. Teo, et al. (2001). "Novel mutations in *ndh* in isoniazid-resistant *Mycobacterium tuberculosis* isolates." *Antimicrob Agents Chemother* 45(7): 2157-2159.
- Lenaerts, A. J., V. Gruppo, et al. (2005). "Preclinical testing of the nitroimidazopyran PA-824 for activity against *Mycobacterium tuberculosis* in a series of in vitro and in vivo models." *Antimicrob Agents Chemother* 49(6): 2294-2301.
- Leung, K. L., C. W. Yip, et al. (2010). "Usefulness of resistant gene markers for predicting treatment outcome on second-line anti-tuberculosis drugs." *J Appl Microbiol* 109(6): 2087-2094.
- Mackanness, G. B. and N. Smith (1952). "The action of isoniazid (isonicotinic acid hydrazide) on intracellular tubercle bacilli." *Am Rev Tuberc* 66(2): 125-133.
- Makarov, V., G. Manina, et al. (2009). "Benzothiazinones kill *Mycobacterium tuberculosis* by blocking arabinan synthesis." *Science* 324(5928): 801-804.
- Manina, G., M. Bellinzoni, et al. (2010). "Biological and structural characterization of the *Mycobacterium smegmatis* nitroreductase NfnB, and its role in benzothiazinone resistance." *Mol Microbiol* 77(5): 1172-1185.

- Marttila, H. J., H. Soini, et al. (1998). "A Ser315Thr substitution in KatG is predominant in genetically heterogeneous multidrug-resistant *Mycobacterium tuberculosis* isolates originating from the St. Petersburg area in Russia." *Antimicrob Agents Chemother* 42(9): 2443-2445.
- Matsumoto, M., H. Hashizume, et al. (2006). "OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice." *PLoS Med* 3(11): e466.
- Matteelli, A., A. C. Carvalho, et al. (2010). "TMC207: the first compound of a new class of potent anti-tuberculosis drugs." *Future Microbiol* 5(6): 849-858.
- Miesel, L., T. R. Weisbrod, et al. (1998). "NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in *Mycobacterium smegmatis*." *J Bacteriol* 180(9): 2459-2467.
- Mikusova, K., R. A. Slayden, et al. (1995). "Biogenesis of the mycobacterial cell wall and the site of action of ethambutol." *Antimicrob Agents Chemother* 39(11): 2484-2489.
- Mitchison, D. A. (1985). "The action of antituberculosis drugs in short-course chemotherapy." *Tubercle* 66(3): 219-225.
- Mitchison, D. A. (1985). "[Mechanisms of the action of drugs in the short-course chemotherapy]." *Bull Int Union Tuberc* 60(1-2): 36-40.
- Morlock, G. P., B. Metchock, et al. (2003). "ethA, inhA, and katG loci of ethionamide-resistant clinical *Mycobacterium tuberculosis* isolates." *Antimicrob Agents Chemother* 47(12): 3799-3805.
- Musser, J. M. (1995). "Antimicrobial agent resistance in mycobacteria: molecular genetic insights." *Clin Microbiol Rev* 8(4): 496-514.
- Musser, J. M., V. Kapur, et al. (1996). "Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of *Mycobacterium tuberculosis* by automated DNA sequencing: restricted array of mutations associated with drug resistance." *Journal of Infectious Diseases* 173(1): 196-202.
- Nair, J., D. A. Rouse, et al. (1993). "The rpsL gene and streptomycin resistance in single and multiple drug-resistant strains of *Mycobacterium tuberculosis*." *Mol Microbiol* 10(3): 521-527.
- Ordway, D., M. Viveiros, et al. (2003). "Clinical concentrations of thioridazine kill intracellular multidrug-resistant *Mycobacterium tuberculosis*." *Antimicrob Agents Chemother* 47(3): 917-922.
- Pasca, M. R., G. Degiacomi, et al. (2010). "Clinical isolates of *Mycobacterium tuberculosis* in four European hospitals are uniformly susceptible to benzothiazinones." *Antimicrob Agents Chemother* 54(4): 1616-1618.
- Paulin, L. G., E. E. Brander, et al. (1985). "Specific inhibition of spermidine synthesis in *Mycobacteria* spp. by the dextro isomer of ethambutol." *Antimicrob Agents Chemother* 28(1): 157-159.
- Petrella, S., E. Cambau, et al. (2006). "Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria." *Antimicrob Agents Chemother* 50(8): 2853-2856.
- Piscitelli, S. C., L. H. Danziger, et al. (1992). "Clarithromycin and azithromycin: new macrolide antibiotics." *Clin Pharm* 11(2): 137-152.

- Protopopova, M., C. Hanrahan, et al. (2005). "Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines." *J Antimicrob Chemother* 56(5): 968-974.
- Quemard, A., J. C. Sacchetti, et al. (1995). "Enzymatic characterization of the target for isoniazid in *Mycobacterium tuberculosis*." *Biochemistry* 34(26): 8235-8241.
- Ramaswamy, S. and J. M. Musser (1998). "Molecular genetic basis of antimicrobial agent resistance in *Mycobacterium tuberculosis*: 1998 update." *Tuber Lung Dis* 79(1): 3-29.
- Ramaswamy, S. V., A. G. Amin, et al. (2000). "Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of *Mycobacterium tuberculosis*." *Antimicrob Agents Chemother* 44(2): 326-336.
- Raynaud, C., M. A. Laneelle, et al. (1999). "Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity." *Microbiology* 145 (Pt 6): 1359-1367.
- Rengarajan, J., C. M. Sasseti, et al. (2004). "The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria." *Mol Microbiol* 53(1): 275-282.
- Robitzek, E. H. and I. J. Selikoff (1952). "Hydrazine derivatives of isonicotinic acid (rimifon marsilid) in the treatment of active progressive caseous-pneumonic tuberculosis; a preliminary report." *Am Rev Tuberc* 65(4): 402-428.
- Rouse, D. A., J. A. DeVito, et al. (1996). "Site-directed mutagenesis of the *katG* gene of *Mycobacterium tuberculosis*: effects on catalase-peroxidase activities and isoniazid resistance." *Mol Microbiol* 22(3): 583-592.
- Rozwarski, D. A., G. A. Grant, et al. (1998). "Modification of the NADH of the isoniazid target (InhA) from *Mycobacterium tuberculosis*." *Science* 279(5347): 98-102.
- Saint-Joanis, B., H. Souchon, et al. (1999). "Use of site-directed mutagenesis to probe the structure, function and isoniazid activation of the catalase/oxidase, KatG, from *Mycobacterium tuberculosis*." *Biochem J* 338 (Pt 3): 753-760.
- Sander, P., A. Meier, et al. (1996). "Ribosomal drug resistance in mycobacteria." *Res Microbiol* 147(1-2): 59-67.
- Scorpio, A., P. Lindholm-Levy, et al. (1997). "Characterization of *pncA* mutations in pyrazinamide-resistant *Mycobacterium tuberculosis*." *Antimicrob Agents Chemother* 41(3): 540-543.
- Scorpio, A. and Y. Zhang (1996). "Mutations in *pncA*, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus." *Nat Med* 2(6): 662-667.
- Sensi, P. (1983). "History of the development of rifampin." *Rev Infect Dis* 5 Suppl 3: S402-406.
- Sharma, S. K. and A. Mohan (2006). "Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis control." *Chest* 130(1): 261-272.
- Singh, R., U. Manjunatha, et al. (2008). "PA-824 kills nonreplicating *Mycobacterium tuberculosis* by intracellular NO release." *Science* 322(5906): 1392-1395.
- Sreevatsan, S., X. Pan, et al. (1996). "Characterization of *rpsL* and *rrs* mutations in streptomycin-resistant *Mycobacterium tuberculosis* isolates from diverse geographic localities." *Antimicrob Agents Chemother* 40(4): 1024-1026.

- Sreevatsan, S., K. E. Stockbauer, et al. (1997). "Ethambutol resistance in *Mycobacterium tuberculosis*: critical role of *embB* mutations." *Antimicrob Agents Chemother* 41(8): 1677-1681.
- Steele, M. A. and R. M. Des Prez (1988). "The role of pyrazinamide in tuberculosis chemotherapy." *Chest* 94(4): 845-850.
- Stover, C. K., P. Warrener, et al. (2000). "A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis." *Nature* 405(6789): 962-966.
- Suter, E. (1952). "Multiplication of tubercle bacilli within phagocytes cultivated in vitro, and effect of streptomycin and isonicotinic acid hydrazide." *Am Rev Tuberc* 65(6): 775-776.
- Takayama, K., E. L. Armstrong, et al. (1979). "Inhibition by ethambutol of mycolic acid transfer into the cell wall of *Mycobacterium smegmatis*." *Antimicrob Agents Chemother* 16(2): 240-242.
- Takayama, K., H. K. Schnoes, et al. (1975). "Site of inhibitory action of isoniazid in the synthesis of mycolic acids in *Mycobacterium tuberculosis*." *J Lipid Res* 16(4): 308-317.
- Takayama, K., L. Wang, et al. (1972). "Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of *Mycobacterium tuberculosis*." *Antimicrob Agents Chemother* 2(1): 29-35.
- Taniguchi, H., B. Chang, et al. (1997). "Molecular analysis of kanamycin and viomycin resistance in *Mycobacterium smegmatis* by use of the conjugation system." *Journal of Bacteriology* 179(15): 4795-4801.
- Telenti, A., P. Imboden, et al. (1993). "Detection of rifampicin-resistance mutations in *Mycobacterium tuberculosis*." *Lancet* 341(8846): 647-650.
- Telenti, A., W. J. Philipp, et al. (1997). "The *emb* operon, a gene cluster of *Mycobacterium tuberculosis* involved in resistance to ethambutol." *Nat Med* 3(5): 567-570.
- Tomasz, A., A. Albino, et al. (1970). "Multiple antibiotic resistance in a bacterium with suppressed autolytic system." *Nature* 227(5254): 138-140.
- Trefzer, C., M. Rengifo-Gonzalez, et al. (2010). "Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-beta-D-ribose 2'-epimerase DprE1 of *Mycobacterium tuberculosis*." *J Am Chem Soc* 132(39): 13663-13665.
- Tsukamura, M. and S. Mizuno (1975). "Cross-resistant relationships among the aminoglycoside antibiotics in *Mycobacterium tuberculosis*." *J Gen Microbiol* 88(2): 269-274.
- van Soolingen, D., R. Hernandez-Pando, et al. (2010). "The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis." *Plos One* 5(9).
- Vannelli, T. A., A. Dykman, et al. (2002). "The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase." *J Biol Chem* 277(15): 12824-12829.
- Via, L. E., P. L. Lin, et al. (2008). "Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates." *Infection and Immunity* 76(6): 2333-2340.
- Vilcheze, C., Y. Av-Gay, et al. (2008). "Mycithiol biosynthesis is essential for ethionamide susceptibility in *Mycobacterium tuberculosis*." *Mol Microbiol* 69(5): 1316-1329.
- Von Groll, A., A. Martin, et al. (2009). "Fluoroquinolone resistance in *Mycobacterium tuberculosis* and mutations in *gyrA* and *gyrB*." *Antimicrob Agents Chemother* 53(10): 4498-4500.

- Wade, M. M. and Y. Zhang (2004). "Mechanisms of drug resistance in *Mycobacterium tuberculosis*." *Front Biosci* 9: 975-994.
- Wallis, R. S., W. Jakubiec, et al. (2011). "Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis." *Antimicrob Agents Chemother* 55(2): 567-574.
- Wayne, L. G. and L. G. Hayes (1996). "An in vitro model for sequential study of shiftdown of *Mycobacterium tuberculosis* through two stages of nonreplicating persistence." *Infection and Immunity* 64(6): 2062-2069.
- Wayne, L. G. and H. A. Sramek (1994). "Metronidazole is bactericidal to dormant cells of *Mycobacterium tuberculosis*." *Antimicrob Agents Chemother* 38(9): 2054-2058.
- Weinstein, E. A., T. Yano, et al. (2005). "Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs." *Proc Natl Acad Sci U S A* 102(12): 4548-4553.
- Williams, K. N., S. J. Brickner, et al. (2009). "Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis." *Am J Respir Crit Care Med* 180(4): 371-376.
- Winder, F. G. and P. B. Collins (1970). "Inhibition by isoniazid of synthesis of mycolic acids in *Mycobacterium tuberculosis*." *J Gen Microbiol* 63(1): 41-48.
- Wong, S. Y., J. S. Lee, et al. (2011). "Mutations in *gidB* confer low-level streptomycin resistance in *Mycobacterium tuberculosis*." *Antimicrob Agents Chemother* 55(6): 2515-2522.
- Xu, C., B. N. Kreiswirth, et al. (1996). "Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant *Mycobacterium tuberculosis*." *Journal of Infectious Diseases* 174(5): 1127-1130.
- Yeager, R. L., W. G. Munroe, et al. (1952). "Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis." *Am Rev Tuberc* 65(5): 523-546.
- Zatman, L. J., N. O. Kaplan, et al. (1954). "Effect of isonicotinic acid hydrazide on diphosphopyridine nucleotidases." *J Biol Chem* 209(2): 453-466.
- Zhang, N., J. B. Torrelles, et al. (2003). "The Emb proteins of mycobacteria direct arabinosylation of lipoarabinomannan and arabinogalactan via an N-terminal recognition region and a C-terminal synthetic region." *Mol Microbiol* 50(1): 69-76.
- Zhang, T., S. Y. Li, et al. (2011). "Short-course Chemotherapy with TMC-207 and Rifapentine in a Murine Model of Latent Tuberculosis Infection." *Am J Respir Crit Care Med*.
- Zhang, Y. (2005). "The magic bullets and tuberculosis drug targets." *Annu Rev Pharmacol Toxicol* 45: 529-564.
- Zhang, Y., B. Heym, et al. (1992). "The catalase-peroxidase gene and isoniazid resistance of *Mycobacterium tuberculosis*." *Nature* 358(6387): 591-593.
- Zhang, Y., A. Scorpio, et al. (1999). "Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of *Mycobacterium tuberculosis* to pyrazinamide." *Journal of Bacteriology* 181(7): 2044-2049.
- Zhang, Y., M. M. Wade, et al. (2003). "Mode of action of pyrazinamide: disruption of *Mycobacterium tuberculosis* membrane transport and energetics by pyrazinoic acid." *J Antimicrob Chemother* 52(5): 790-795.



Understanding Tuberculosis - New Approaches to Fighting Against Drug Resistance

Edited by Dr. Pere-Joan Cardona

ISBN 978-953-307-948-6

Hard cover, 376 pages

Publisher InTech

Published online 15, February, 2012

Published in print edition February, 2012

In 1957, a Streptomyces strain, the ME/83 (*S.mediterranei*), was isolated in the Lepetit Research Laboratories from a soil sample collected at a pine arboretum near Saint Raphael, France. This drug was the base for the chemotherapy with Streptomycin. The euphoria generated by the success of this regimen led to the idea that TB eradication would be possible by the year 2000. Thus, any further drug development against TB was stopped. Unfortunately, the lack of an accurate administration of these drugs originated the irruption of the drug resistance in *Mycobacterium tuberculosis*. Once the global emergency was declared in 1993, seeking out new drugs became urgent. In this book, diverse authors focus on the development and the activity of the new drug families.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Anastasia S. Kolyva and Petros C. Karakousis (2012). Old and New TB Drugs: Mechanisms of Action and Resistance, *Understanding Tuberculosis - New Approaches to Fighting Against Drug Resistance*, Dr. Pere-Joan Cardona (Ed.), ISBN: 978-953-307-948-6, InTech, Available from:

<http://www.intechopen.com/books/understanding-tuberculosis-new-approaches-to-fighting-against-drug-resistance/old-and-new-tb-drugs-mechanisms-of-action-and-resistance>

INTECH

open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.